Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Sep 1.
Published in final edited form as: Curr Opin Clin Nutr Metab Care. 2024 Jun 7;27(5):397–401. doi: 10.1097/MCO.0000000000001050

Assessment of iron status

Ann Von Holle 1
PMCID: PMC11370657  NIHMSID: NIHMS2015756  PMID: 38847622

Abstract

Purpose of review

Iron is an essential trace element in human health that can be harmful at abnormal levels such as iron overload or deficiency. Measured iron status in the body can depend on health outcomes experienced by the individual and this can complicate its accurate assessment. This review will highlight recent research on iron assessment in the literature.

Recent findings

Research on iron assessment within the past 18 months included some common themes spanning new methods and biomarkers, as well as existing problems in assessing iron deficiency and overload. Heterogeneity in associations between inflammation and iron levels are reflected across different inflammatory biomarkers. New methods relevant to low- and high-resource settings may improve assessment in tissues with iron deficiency and overload. Consensus papers outlined best practices when using MRI to assess iron status. Outside of newer methods, traditional serum markers are the subject of a call for updated guidance when assessing iron status.

Summary

Research continues on the topic of iron assessment, underlying its complex metabolism in the body and resulting challenges in assessment. Current literature underscores progress to make iron assessment more accessible, improve existing methods, and update current assessment methods so they correspond with recent research to improve human health.

Keywords: Iron, Anemia, Iron-Deficiency, Biomarkers, Iron Overload, Outcome Assessment, Health Care

Introduction

Iron is an essential trace element necessary for human health. However, at abnormal levels, iron can have adverse health outcomes in the body arising from mechanisms including nutritional intake, genetics, and absorption. A large proportion of the world-wide population has iron levels requiring assessment and intervention. For example, globally, one in four women are estimated to have iron deficiency1. Assessment of iron requires an understanding of its homeostasis in the body, a complex process reflected by the ongoing search for meaningful, accurate and non-invasive measures of assessment. Given its complex role in human health, iron status assessment relates to different target populations and topics such as the prevalence of iron deficiency and overload as well as specific patient populations for whom iron levels require intervention. As noted in the following literature review, assessment of iron status using common serum indicators may not be ideal2 and may not represent the true iron status of an individual thus impairing efforts at treatment and intervention. Highlighting advances in methods, information, biomarkers relating to iron assessment can inform future research on iron as both an outcome and exposure. The aim of this paper is to summarize recent studies that have a primary focus on iron assessment, categorized by most frequent topics in the literature from the past 18 months.

Factors influencing the assessment of iron status

There are many factors associated with iron status, which can be used to better understand the limitations of its assessment and potential roles for confounders when evaluating iron status as an exposure.

Inflammation

Inflammation is a common and well-known factor influencing iron assessment and is described as a biological confounding factor. Ferritin, commonly used to assess iron stores, is an acute-phase protein that increases in response to inflammation making it less useful as a biomarker. Distinguishing anemia of inflammation from true iron deficiency anemia remains a gap in knowledge, and MRI offers the potential to assess iron content in multiple tissues including in the liver, pancreas and heart3. This approach was noted as having the potential to better identify and treat people with anemia of inflammation, typically characterized with lower serum iron and transferrin saturation and higher ferritin levels compared to people with anemia of inflammation and iron deficiency anemia.

Recent research demonstrates heterogeneity in associations between iron status and inflammation suggesting that the mechanism explaining iron levels and inflammatory markers is not consistent across observational studies. One study using cluster analysis to categorize the inflammatory content of diet derived from dietary records, body size, and biomarkers4 found no association between inflammatory status and iron status biomarkers but did show an inverse association between total iron-binding capacity and inflammatory diet content. When focusing on associations between inflammatory biomarkers and anemia status in an older sample of adults ≥ 65 years5, inflammatory biomarkers such as TNF-alpha, HPC, and IL-1-beta were higher in the group defined as having anemia (based on hemoglobin levels), but not the CRP biomarker. When examining another type of inflammation biomarker based on cell counts of neutrophil, lymphocytes, and platelets, authors of a study6 based on a U.S. population found an inverse relationship with serum ferritin, which is contrary to a positive relationship commonly found with inflammatory markers such as CRP. The authors hypothesized that ferritin may be positively associated with cell damage-based biomarkers such as CRP, but not cell counts in the systemic immune-inflammation composite marker used in their study, suggesting inconsistent associations between iron assessment and biomarkers for inflammation. Last, in another study of indigenous lactating mothers in Panama of childbearing age, there was no association between inflammation indicators and anemia, but there was a positive association with hepcidin and ferritin alongside an inverse association with serum iron7. These studies include populations from different countries as well as different age groups, which, alongside the observational character of all these studies, could contribute to the variation in results.

Iron assessment in women

Research focusing on factors such as heavy menstrual bleeding8 or weight change among young women with overweight9 suggest these are subgroups that are important candidates for iron assessment. In a group of adolescents presenting to an emergency department for heavy menstrual bleeding (n=258), a large proportion of those with an iron study (n=23) had iron deficiency (78%) and anemia (92%). These findings suggest the need for increasing iron status assessments in adolescents with heavy menstrual bleeding, and they support existing evidence that heavy bleeding is a predictor of lower iron stores. A study reporting results from a randomized weight loss intervention9* hypothesized weight loss would result in lower inflammation and subsequently alter iron levels. As expected, following the intervention, weight loss was associated with lower inflammatory markers, including CRP and hepcidin, as well as higher levels for hemoglobin, ferritin, and serum iron. Interestingly, participants in the weight loss intervention group consumed less iron but had higher iron levels than the control group, suggesting a mechanism unrelated to iron intake and perhaps relating to inflammation.

Other studies assessed multiple predictors of iron status in women during their childbearing years7 and/or menopause10. In an observational study of lactating indigenous women in Panama7 discussed above, CRP, an inflammatory marker, was positively associated with hepcidin and ferritin and inversely associated with serum iron. In the study of survey-based self-reported responses from participants, recent blood donation was a factor having the strongest association with iron outcomes for both pre- and postmenopausal women10.

Altogether, these studies suggest that the association between inflammation and iron varies across populations. At the same time these studies reinforce the existing literature stressing the consideration of concurrent inflammation when assessing iron content in people. Furthermore, defining alternative thresholds for conditions such as anemia and iron overload also requires additional research to better understand the role and mechanism underlying associations between inflammation and iron status in subgroups.

Non-serum based assessment methods

Alternate methods to iron assessment through classic serum iron biomarkers from standard assays such as serum iron, ferritin, and transferrin2 can be useful and fill gaps in access to standard tests and tissue-specific detection. A new method11, measuring concentrations of apotransferrin in EDTA-treated plasma, is proposed as a proxy to unsaturated iron-binding capacity (UIBC) and has fewer requirements for equipment making it suitable for low resource settings. Similarly, there was a validation of VitMin Lab s-ELISA assays12 for iron levels such as ferritin compared to traditional iron measures from NHANES. More than 88% of the ferritin samples in this study were within 30% of the referent and comparable prevalence estimates for abnormal measures based on ferritin, making it a candidate for use in low-resource settings. When compared to the s-ELISA assay, another study noted that the 7-plex assay13, another candidate assay to assess ferritin in low-resource settings, had ferritin measures that were correlated but consistently higher than the referent lessening its diagnostic value.

Iron levels measured in nails present a less invasive and easier to store resource, but a recent study comparing common serum iron measures to iron levels in nails14 did not find substantive associations between these two biomarkers. When measuring iron levels, nails may not offer a good proxy to serum-based measures. A different study15 evaluating a device to assess ferritin in blood using capillary blood samples, validated and compared the new method to the traditional method using venous serum and found a strong correlation (r2 = 0.86) between the two. When using this method to diagnose iron deficiency using a WHO cutoff, they found a sensitivity of 0.90 and specificity of 0.96. This method has advantages in terms of cost and accessibility compared to more time-intensive and invasive methods. Another recent report detailed a prototype for real-time ferritin detection using a novel biosensor16. Pending future development and scaling of this method, it has potential to provide iron assessment in point-of-care settings requiring lower costs of detection. These new methods offer progress towards increasing iron assessment capabilities in low-resource settings.

Artificial intelligence may have a potential role in the assessment of iron status, especially in its ability to reach larger groups of people, but this nascent method requires more development17. The possibility to assess iron deficiency anemia with a smartphone app and artificial intelligence was explored by evaluating images of conjunctiva18. One of their approaches demonstrated a sensitivity of 79% and specificity of 74%. Another study using machine learning methods to classify four different types of anemia (beta thalassemia trait, hemoglobin E, iron deficiency anemia, and specific combinations of the three prior types) conditional on a person being diagnosed with anemia19 demonstrated a sensitivity exceeding 98%. With larger and more diverse training sets these methods could also be useful in low-resource settings with less access to traditional serum-based assessment methods.

MRI methods, used to assess iron status and more likely to be available in high-resource settings, have capabilities superior to common serum-based assays in detecting iron content in tissues. As discussed above, a study assessing iron retention in patients with anemia of inflammation, confirmed findings from animal models of iron retention in macrophages3. These findings point towards improved biomarker thresholds to assess iron deficiency in patients with inflammatory conditions. In a group of thalassaemic patients, an MRI method evaluated iron overload in heart, liver and pancreas tissues to measure chelation therapy response20. Interestingly, in this study, the authors found that serum ferritin decreased before iron overload in the liver suggesting that decreasing serum ferritin signaled improvement in iron overload in other tissues. Another recent study also found a positive association between liver and cardiac overload and serum ferritin measures21. However, while useful in measuring iron overload, serum ferritin cannot provide tissue-specific iron levels.

When validating MRI technology using in vitro, in-vivo, and ex-vivo means to assess the molecular state of iron in the brain, a recent study suggests MRI is also useful as a non-invasive means to assess iron status in brain tissue22**. Among some of their findings, the authors were able to detect patterns of iron homeostasis in brain tumors of meningioma patients and suggested the new method can be used in non-invasive research into the human brain. Last, a recent report outlined best practices for quantifying liver iron content using MRI, based on expert panel recommendations and a literature review from the last two decades23. These guidelines can provide better alignment of future research methods focusing on tissue-specific iron level assessment. Overall, these recent papers demonstrate the expanding scope of tissue-specific detection of iron levels that can provide a better understanding of iron metabolism.

Abnormal levels: iron overload and deficiency

Iron deficiency and iron overload are prevalent health outcomes, and their assessment remains a source of potential misclassification with existing assessment methods. Research is active given the lack of consensus on the definition of these outcomes.

MRI technology can provide an alternate, and less invasive, measure for iron overload in the liver23,24. Iron accumulation in the body due to metabolic hyperferritinemia is the primary topic of a comprehensive literature review, which concludes with an updated definition and staging system with cutoffs of liver iron concentrations assessed with MRI25. This characterization of iron accumulation is meant to advance research and guide decision-making for metabolic hyperferritinemia. Another group introduced and validated the concept of a liver iron index as measured through MRI instead of biopsy24, finding this measure to be effective in distinguishing between major and minor iron overload in patients with hyperferritinemia.

Iron deficiency is an adverse health outcome with biomarker cutoffs that depend on the health status of an individual, and, if adhering to general iron thresholds for diagnosis, may result in failure to identify people with low iron stores who could receive therapy to improve their health status. Outdated guidelines for the assessment of iron deficiency are outlined in a recent essay on iron deficiency in the United States26, prompting a call for improved and systematic recommendations of laboratory results. Similarly, in people with inflammatory conditions, iron deficiency does not have a consensus on its assessment with common parameters such as ferritin. Among patients with inflammatory conditions around half may be deficient in iron, noted in a recent review27 that advocates for assessment of iron deficiency in all people with chronic inflammatory diseases such as chronic heart failure, chronic kidney disease, inflammatory bowel disease, and cancer.

A recent review of the potential for hepcidin as a new biomarker for anemia28 discusses the potential to fill existing gaps in iron deficiency assessment. Given the role of hepcidin in iron homeostasis, it may fulfill the need for alternative biomarkers when assessing iron status in certain groups, including those experiencing chronic disease driven inflammatory anemia and infants with iron deficiency. Using patient records, a recent study evaluated hepcidin as a means to differentiate between iron-refractory iron-deficiency anemia and anemia associated with gastrointestinal causes29. Using a combination of hepcidin and oral iron absorption tests, the authors found unique associations suggesting different causal mechanisms such as menstrual blood loss, genetic conditions, and malabsorption. Incorporating hepcidin as a biomarker into existing methods may improve assessment of types of iron deficiency in people with inflammation.

Conclusion

This review of recent literature focusing on iron assessment addressed some common themes including influencing factors, new methods, new biomarkers, and existing problems in iron assessment for conditions such as iron deficiency and overload. Some of these findings show gaps in existing iron assessment approaches: iron deficiency in people with inflammatory conditions being one example. More sophisticated screening methods such as MRIs are in a position to advance the understanding of areas such as tissue-specific iron metabolism, which can better inform interventions and non-invasive research. The mechanisms by which iron levels change are better defined than the messages regarding how and in who to assess iron levels, which is motivating some of the discussed research. In summary, this review highlights recent research on iron assessment that focuses on increasing access, updating standards, and developing new methods to improve accuracy of diagnoses and increase interventions to improve health.

Key findings.

  • Screening methods such as MRIs are advancing the understanding of tissue-specific iron metabolism, which can better inform interventions and non-invasive research.

  • Gaps in the assessment of iron deficiency still exist for the general population and among those with inflammatory conditions with recent publications advocating for change.

  • Some research focuses on novel approaches to iron assessment, which may increase its accessibility beyond traditional lab-based measures.

Acknowledgements

This research was supported in part by the Intramural Research Program of the NIH.

Footnotes

Conflicts of Interest:

Ann Von Holle has no conflict of interest to report.

References

  • 1.Gardner WM, Razo C, McHugh TA, et al. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021. Lancet Haematol. 2023;10(9):e713–e734. doi: 10.1016/S2352-3026(23)00160-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Pfeiffer CM, Looker AC. Laboratory methodologies for indicators of iron status: strengths, limitations, and analytical challenges. Am J Clin Nutr. 2017;106(Suppl 6):1606S–1614S. doi: 10.3945/ajcn.117.155887 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lanser L, Plaikner M, Schroll A, et al. Tissue iron distribution in patients with anemia of inflammation: Results of a pilot study. Am J Hematol. 2023;98(6):890–899. doi: 10.1002/ajh.26909 [DOI] [PubMed] [Google Scholar]
  • 4.Doherty JL, Larvie DY, Shivappa N, Hebert JR, Armah SM. Inflammatory diets are associated with lower total iron binding capacity in sera of young adults. Int J Vitam Nutr Res Int Z Vitam-Ernahrungsforschung J Int Vitaminol Nutr. 2023;93(1):9–17. doi: 10.1024/0300-9831/a000697 [DOI] [PubMed] [Google Scholar]
  • 5.Wacka E, Wawrzyniak-Gramacka E, Tylutka A, Morawin B, Gutowicz M, Zembron-Lacny A. The Role of Inflammation in Age-Associated Changes in Red Blood System. Int J Mol Sci. 2023;24(10):8944. doi: 10.3390/ijms24108944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Zhang Y, Meng Y, Chen M, et al. Correlation between the systemic immune-inflammation indicator (SII) and serum ferritin in US adults: a cross-sectional study based on NHANES 2015–2018. Ann Med. 2023;55(2):2275148. doi: 10.1080/07853890.2023.2275148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gonzalez-Fernandez D, Nemeth E, Pons EDC, et al. Multiple indicators of undernutrition, infection, and inflammation in lactating women are associated with maternal iron status and infant anthropometry in panama: The MINDI cohort. NUTRIENTS. 2022;14(17). doi: 10.3390/nu14173497 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Stoffers VL, Weyand AC, Quint EH, Rosen MW. Assessment of iron status in adolescents presenting to the emergency department with heavy menstrual bleeding. Pediatr Emerg CARE. 2022;38(5):E1266–E1270. doi: 10.1097/PEC.0000000000002591 [DOI] [PubMed] [Google Scholar]
  • 9. Alshwaiyat NM, Ahmad A, Al-Jamal HAN. Effect of diet-induced weight loss on iron status and its markers among young women with overweight/obesity and iron deficiency anemia: a randomized controlled trial. Front Nutr. 2023;10:1155947. doi: 10.3389/fnut.2023.1155947. * The first randomized control design study in a sample of women with overweight/obesity and iron deficiency anemia, which found associations between weight loss and iron status not explained by higher iron intake.
  • 10.Von Holle A, O’Brien KM, Janicek R, Weinberg CR. Development and validation of a prediction model for iron status in a large U.S. cohort of women. Sci Rep. 2023;13(1):17309. doi: 10.1038/s41598-023-42993-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Guo R, Gao J, Hui L, et al. An Improved Method for Quick Quantification of Unsaturated Transferrin. Biosensors. 2022;12(9):708. doi: 10.3390/bios12090708 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fischer CM, Zhang M, Sternberg MR, et al. The VitMin Lab Sandwich-ELISA Assays for Iron and Inflammation Markers Compared Well with Clinical Analyzer Reference-Type Assays in Subsamples of the Nepal National Micronutrient Status Survey. J Nutr. 2022;152(1):350–359. doi: 10.1093/jn/nxab355 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chimhashu TL, Verhoef H, Symington EA, et al. Comparison of test performance of two commonly used multiplex assays to measure micronutrient and inflammatory markers in serum: results from a survey among pregnant women in South Africa. Br J Nutr. 2024;131(2):248–255. doi: 10.1017/S0007114523001782 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Von Holle A, O’Brien KM, Sandler DP, et al. Toenail and serum levels as biomarkers of iron status in pre- and postmenopausal women: correlations and stability over eight-year follow-up. Sci Rep. 2024;14(1):1682. doi: 10.1038/s41598-023-50506-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Fiddler JL, McBurney MI, Haas JD. Using Capillary Whole Blood to Quantitatively Measure Ferritin: A Validation Trial of a Point-of-Care System. Nutrients. 2023;15(6):1305. doi: 10.3390/nu15061305 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gautam N, Chattopadhyay S, Kar S, Sarkar A. Real-time detection of plasma ferritin by electrochemical biosensor developed for biomedical analysis. J Pharm Biomed Anal. 2023;235:115579. doi: 10.1016/j.jpba.2023.115579 [DOI] [PubMed] [Google Scholar]
  • 17.Halfon P, Penaranda G, Ringwald D, et al. Laboratory tests for investigating anemia: From an expert system to artificial intelligence. Pract Lab Med. 2024;39:e00357. doi: 10.1016/j.plabm.2024.e00357 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Dimauro G, Griseta ME, Camporeale MG, Clemente F, Guarini A, Maglietta R. An intelligent non-invasive system for automated diagnosis of anemia exploiting a novel dataset. Artif Intell Med. 2023;136:102477. doi: 10.1016/j.artmed.2022.102477 [DOI] [PubMed] [Google Scholar]
  • 19.Saputra DCE, Sunat K, Ratnaningsih T. A New Artificial Intelligence Approach Using Extreme Learning Machine as the Potentially Effective Model to Predict and Analyze the Diagnosis of Anemia. Healthcare. 2023;11(5):697. doi: 10.3390/healthcare11050697 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Chapchap EC, Silva MMA, de Assis RA, et al. Cardiac iron overload evaluation in thalassaemic patients using T2* magnetic resonance imaging following chelation therapy: a multicentre cross-sectional study. Hematol Transfus CELL Ther. 2023;45(1):7–15. doi: 10.1016/j.htct.2021.01.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Abdi S, Taheri N, Zahedi Haghighi F, et al. The relationship of myocardial and liver T2* values with cardiac function and laboratory findings in transfusion-dependent thalassemia major patients: A retrospective cardiac MRI study. J Cardiovasc Thorac Res. 2023;15(2):86–92. doi: 10.34172/jcvtr.2023.31592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Filo S, Shaharabani R, Bar Hanin D, et al. Non-invasive assessment of normal and impaired iron homeostasis in the brain. Nat Commun. 2023;14(1):5467. doi: 10.1038/s41467-023-40999-z ** This paper introduces a new MRI technology reflecting iron homeostasis in the human brain with in vitro, in vivo, and ex vivo validation analyses. This new method has the potential to contribute to non-invasive research in the living human brain.
  • 23.Reeder SB, Yokoo T, Franca M, et al. Quantification of Liver Iron Overload with MRI: Review and Guidelines from the ESGAR and SAR. RADIOLOGY. 2023;307(1). doi: 10.1148/radiol.221856 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Moris W, Verbeek J, Bakers FC, et al. Hyperferritinemia and liver iron content determined with MRI: Reintroduction of the liver iron index. Clin Res Hepatol Gastroenterol. 2023;47(10). doi: 10.1016/j.clinre.2023.102224 [DOI] [PubMed] [Google Scholar]
  • 25.Valenti L, Corradini E, Adams LA, et al. Consensus Statement on the definition and classification of metabolic hyperferritinaemia. Nat Rev Endocrinol. 2023;19(5):299–310. doi: 10.1038/s41574-023-00807-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Jefferds MED, Mei Z, Addo Y, et al. Iron Deficiency in the United States: Limitations in Guidelines, Data, and Monitoring of Disparities. Am J Public Health. 2022;112(S8):S826–S835. doi: 10.2105/AJPH.2022.306998 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Cacoub P, Choukroun G, Cohen-Solal A, et al. Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action. J Intern Med. 2022;292(4):542–556. doi: 10.1111/joim.13503 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Fathi ZH, Mohammad JA, Younus ZM, Mahmood SM. Hepcidin as a potential biomarker for the diagnosis of anemia. Turk J Pharm Sci. 2022;19(5):603–609. doi: 10.4274/tjps.galenos.2021.29488 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Loveikyte R, van den Berg Y, de Jong A, Vlasveld LT. The role of hepcidin and an oral iron absorption test in identifying the root cause of iron-restricted anemia. ACTA Haematol. Published online November 16, 2023. doi: 10.1159/000535275 [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES